These reports support the notion that the genetic alterations upregulated in our study are associated with worse prognosis and further validation is required to confirm that these gene signatures are potential biomarkers for recurrence in early stage HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.